InsiderTrades.com logo
2024 Election Year Stocks: Uncover Hidden Gems!
From Darwin   |   Ad
In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.
Secure your copy now by clicking this link.
John Valliant net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

John Valliant Biography and Net Worth

CEO of Fusion Pharmaceuticals

Dr. Valliant is Founder and Chief Executive Officer of Fusion Pharmaceuticals. Dr. Valliant has been instrumental in securing both investment and scientific and medical collaborations with the industrial and academic partners of Fusion.

Prior to Fusion, Dr. Valliant founded the Centre for Probe Development and Commercialization (CPDC), a radiopharmaceutical research and development centre of excellence established in 2008 through funding from the Federal and Provincial governments, industry and academic partners. The CPDC is focused on discovering, developing and distributing the next generation of molecular imaging probes. The CPDC also plays an important role in Canada’s health care system, manufacturing and delivering a reliable, daily supply of imaging probes to hospitals and clinics nationally and internationally.
Dr. Valliant is also a Professor in the Department of Chemistry and Chemical Biology at McMaster University.

What is John Valliant's net worth?

The estimated net worth of John Valliant is at least $7.00 million as of April 25th, 2022. Dr. Valliant owns 324,805 shares of Fusion Pharmaceuticals stock worth more than $6,999,548 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Valliant may own. Additionally, Dr. Valliant receives an annual salary of $911,340.00 as CEO at Fusion Pharmaceuticals. Learn More about John Valliant's net worth.

How old is John Valliant?

Dr. Valliant is currently 53 years old. There are 5 older executives and no younger executives at Fusion Pharmaceuticals. Learn More on John Valliant's age.

What is John Valliant's salary?

As the CEO of Fusion Pharmaceuticals Inc., Dr. Valliant earns $911,340.00 per year. Learn More on John Valliant's salary.

How do I contact John Valliant?

The corporate mailing address for Dr. Valliant and other Fusion Pharmaceuticals executives is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. Fusion Pharmaceuticals can also be reached via phone at 289-799-0891 and via email at [email protected]. Learn More on John Valliant's contact information.

Has John Valliant been buying or selling shares of Fusion Pharmaceuticals?

John Valliant has not been actively trading shares of Fusion Pharmaceuticals over the course of the past ninety days. Most recently, John Valliant sold 4,511 shares of the business's stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $6.03, for a transaction totalling $27,201.33. Following the completion of the sale, the chief executive officer now directly owns 318,147 shares of the company's stock, valued at $1,918,426.41. Learn More on John Valliant's trading history.

Who are Fusion Pharmaceuticals' active insiders?

Fusion Pharmaceuticals' insider roster includes Steven Gannon (Director), and John Valliant (CEO). Learn More on Fusion Pharmaceuticals' active insiders.

John Valliant Insider Trading History at Fusion Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/27/2022Sell4,511$6.03$27,201.33318,147View SEC Filing Icon  
4/25/2022Sell2,036$6.03$12,277.08324,805View SEC Filing Icon  
4/20/2022Sell367$6.02$2,209.34327,763View SEC Filing Icon  
4/13/2022Sell11,994$6.41$76,881.54328,130View SEC Filing Icon  
4/11/2022Sell2,600$7.37$19,162.00358,379View SEC Filing Icon  
4/8/2022Sell826$7.52$6,211.52360,979View SEC Filing Icon  
4/6/2022Sell100$7.58$758.00360,979View SEC Filing Icon  
3/30/2022Sell300$7.52$2,256.00View SEC Filing Icon  
3/28/2022Sell9,600$7.55$72,480.00View SEC Filing Icon  
3/25/2022Sell500$7.42$3,710.00View SEC Filing Icon  
3/23/2022Sell100$7.50$750.00View SEC Filing Icon  
3/21/2022Sell1,500$7.47$11,205.00View SEC Filing Icon  
3/17/2022Sell900$7.51$6,759.00View SEC Filing Icon  
3/7/2022Sell3,100$6.99$21,669.00View SEC Filing Icon  
3/4/2022Sell8,400$7.32$61,488.00View SEC Filing Icon  
2/28/2022Sell3,100$7.40$22,940.00View SEC Filing Icon  
2/24/2022Sell2,500$7.41$18,525.00View SEC Filing Icon  
2/22/2022Sell4,100$7.85$32,185.00View SEC Filing Icon  
2/17/2022Sell1,700$7.98$13,566.00View SEC Filing Icon  
2/15/2022Sell12,600$8.33$104,958.00View SEC Filing Icon  
See Full Table

John Valliant Buying and Selling Activity at Fusion Pharmaceuticals

This chart shows John Valliant's buying and selling at Fusion Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fusion Pharmaceuticals Company Overview

Fusion Pharmaceuticals logo
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.
Read More

Today's Range

Now: $21.55
Low: $21.55
High: $21.55

50 Day Range

MA: $21.50
Low: $21.38
High: $21.55

2 Week Range

Now: $21.55
Low: $2.31
High: $21.60

Volume

N/A

Average Volume

1,692,620 shs

Market Capitalization

$1.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
2024 Election Year Stocks: Uncover Hidden Gems!
From Darwin   |   Ad
In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.
Secure your copy now by clicking this link.